{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:53:33Z","timestamp":1767855213923,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-193"],"award-info":[{"award-number":["2022-PUMCH-A-193"]}]},{"name":"National Key R&D Program of China, Ministry of Science and Technology of the People\u2019s Republic of China","award":["2022YFC2304605"],"award-info":[{"award-number":["2022YFC2304605"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05690-3","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T19:03:12Z","timestamp":1709751792000},"page":"3667-3675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Jia","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-nan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"issue":"11","key":"5690_CR1","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D\u2019Sa S et al (2020) Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol 7(11):e827\u2013e837","journal-title":"Lancet Haematol"},{"issue":"2","key":"5690_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.26796","volume":"98","author":"MA Gertz","year":"2023","unstructured":"Gertz MA (2023) Waldenstr\u00f6m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol 98(2):348\u2013358","journal-title":"Am J Hematol"},{"issue":"20","key":"5690_CR3","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","volume":"118","author":"SF Elsawa","year":"2011","unstructured":"Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM et al (2011) Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 118(20):5540\u20135549","journal-title":"Blood"},{"issue":"5","key":"5690_CR4","volume":"1877","author":"B Wang","year":"2022","unstructured":"Wang B, Wang M, Ao D, Wei X (2022) CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer. Biochim Biophys Acta 1877(5):188799","journal-title":"Biochim Biophys Acta"},{"key":"5690_CR5","doi-asserted-by":"publisher","first-page":"1197112","DOI":"10.3389\/fimmu.2023.1197112","volume":"14","author":"K Minagawa","year":"2023","unstructured":"Minagawa K, Wakahashi K, Fukui C, Kawano Y, Kawano H, Suzuki T et al (2023) Tfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic mice. Front Immunol 14:1197112","journal-title":"Front Immunol"},{"issue":"2","key":"5690_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1046\/j.1365-2141.2002.03832.x","volume":"119","author":"H Husson","year":"2002","unstructured":"Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G et al (2002) CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol 119(2):492\u2013495","journal-title":"Br J Haematol"},{"issue":"2","key":"5690_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/1055-9965.EPI-12-1122","volume":"22","author":"SK Hussain","year":"2013","unstructured":"Hussain SK, Zhu W, Chang SC, Breen EC, Vendrame E, Magpantay L et al (2013) Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 22(2):295\u2013307","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"5690_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1182\/blood-2013-01-481077","volume":"122","author":"MP Purdue","year":"2013","unstructured":"Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, Lan Q, Park JH et al (2013) A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood 122(6):951\u2013957","journal-title":"Blood"},{"issue":"41","key":"5690_CR9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105822118","volume":"118","author":"T Aoki","year":"2021","unstructured":"Aoki T, Chong LC, Takata K, Milne K, Marshall A, Chavez EA et al (2021) Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Proc Natl Acad Sci USA 118(41):e2105822118","journal-title":"Proc Natl Acad Sci USA"},{"key":"5690_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.leukres.2019.04.007","volume":"81","author":"YY Wu","year":"2019","unstructured":"Wu YY, Cai H, Zhao AL, Zhang L, Zhou DB, Cao XX, Li J (2019) The role of high serum CXCL13 level in Waldenstr\u00f6m macroglobulinemia. Leuk Res 81:50\u201355","journal-title":"Leuk Res"},{"issue":"11","key":"5690_CR11","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.3324\/haematol.2017.172627","volume":"102","author":"JM Vos","year":"2017","unstructured":"Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P et al (2017) CXCL13 levels are elevated in patients with Waldenstr\u00f6m macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica 102(11):e452\u2013e455","journal-title":"Haematologica"},{"issue":"2","key":"5690_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al (2003) Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol 30(2):110\u2013115","journal-title":"Semin Oncol"},{"issue":"18","key":"5690_CR13","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163\u20134170","journal-title":"Blood"},{"issue":"2","key":"5690_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G et al (2013) Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 160(2):171\u2013176","journal-title":"Br J Haematol"},{"issue":"8","key":"5690_CR15","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/cancers12082311","volume":"12","author":"BA Campbell","year":"2020","unstructured":"Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM (2020) Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma. Cancers (Basel) 12(8):2311","journal-title":"Cancers (Basel)"},{"issue":"11","key":"5690_CR16","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","volume":"33","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E et al (2019) A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia 33(11):2654\u20132661","journal-title":"Leukemia"},{"issue":"24","key":"5690_CR17","doi-asserted-by":"publisher","first-page":"39218","DOI":"10.18632\/oncotarget.16836","volume":"8","author":"L Ping","year":"2017","unstructured":"Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y et al (2017) The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget 8(24):39218\u201339229","journal-title":"Oncotarget"},{"issue":"1","key":"5690_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-015-0068-1","volume":"16","author":"E Klimatcheva","year":"2015","unstructured":"Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M et al (2015) CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol 16(1):1\u201317","journal-title":"BMC Immunol"},{"issue":"21","key":"5690_CR19","first-page":"2615","volume":"141","author":"A Sacco","year":"2023","unstructured":"Sacco A, Desantis V, Celay J, Giustini V, Rigali F, Savino F et al (2023) Targeting the immune microenvironment in Waldenstr\u00f6m macroglobulinemia via halting the CD40\/CD40-ligand axis. Blood 141(21):2615\u20132628","journal-title":"Blood"},{"issue":"1","key":"5690_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s12967-022-03798-6","volume":"20","author":"H Sun","year":"2022","unstructured":"Sun H, Fang T, Wang T, Yu Z, Gong L, Wei X et al (2022) Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenstr\u00f6m macroglobulinemia. J Transl Med 20(1):576","journal-title":"J Transl Med"},{"issue":"9","key":"5690_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Zhang Y, Wang D, Hu X, Zhang Z (2022) Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. Nature Cancer 3(9):1123\u20131136","journal-title":"Nature Cancer"},{"issue":"3","key":"5690_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","volume":"3","author":"M Cohen","year":"2022","unstructured":"Cohen M, Giladi A, Barboy O, Hamon P, Li B, Zada M et al (2022) The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nature Cancer 3(3):303\u2013317","journal-title":"Nature Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05690-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:10:23Z","timestamp":1724836223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05690-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5690"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05690-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"17 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the ethical standards of the Declaration of Helsinki, informed consent was obtained from all patients, and the study was approved by the Peking Union Medical College Hospital Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}